United Therapeutics Corp. (NASDAQ: UTHR) posted record revenue and profits in 2022, driven by torrid sales of its key drugs, and it’s projecting growth to accelerate even more in the years ahead. The Silver Spring drugmaker ended the year with more patients than ever using its products and the most cash on hand in its 27-year history, CEO Martine Rothblatt told analysts Wednesday on the company’s fourth-quarter earnings call.
Silver Spring’s United Therapeutics posted record results last year. Here’s how it plans to top that.
February 23, 2023
